化学
小分子
计算生物学
剪接
DNA
组合化学
癌症研究
基因
生物化学
生物
作者
Archana Bhumireddy,N.V.M. Rao Bandaru,B. Raghurami Reddy,Suraj T. Gore,Subhendu Mukherjee,Wesley Roy Balasubramanian,Vipin Kumar,Krishna Satya A,Kondapalli Venkata Gowri Chandra Sekhar,Kavitha Nellore,Chandrasekhar Abbineni,Susanta Samajdar
标识
DOI:10.1016/j.bmcl.2021.128448
摘要
Multiple Splice variants of AR have been reported in the past few years. These splice variants are upregulated in most cases of CRPC resulting in poor prognosis. Most of these variants lack the ligand binding domain (LBD) but still bind to DNA resulting in constitutive activation of downstream targets. The AR-V7 splice variant has been characterized extensively and current clinical trials in CRPC are exploring the use of AR-V7 as a biomarker. New therapeutic molecules that selectively target AR-V7 are also being explored. However, there is a dearth of information available on the selectivity, phenotypic responses in AR-V7 dependent cell lines and pharmacokinetic properties of such molecules. Using our proprietary computational algorithms and rational SAR optimization, we have developed a potent and selective AR-V7 degrader from a known AR DNA binding domain (DBD) binder. This molecule effectively degraded AR-V7 in a CRPC cell line and demonstrated good oral bioavailability in mouse PK studies. This tool compound can be used to evaluate the pharmacological effects of AR-V7 degraders. Further exploration of SAR can be pursued to develop more optimized lead compounds.
科研通智能强力驱动
Strongly Powered by AbleSci AI